{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:09:39Z","timestamp":1776323379523,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12325-024-03028-z","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T07:28:51Z","timestamp":1732865331000},"page":"1393-1418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Baseline Characteristics of the DISCOVER CKD Prospective Cohort"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04034992","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Carol","family":"Pollock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ofori-Asenso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose","family":"Garcia Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Pentakota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"3028_CR1","doi-asserted-by":"publisher","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","volume":"20","author":"J Sundstrom","year":"2022","unstructured":"Sundstrom J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4\u00a0million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100438.","journal-title":"Lancet Reg Health Eur"},{"issue":"10225","key":"3028_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3.","journal-title":"Lancet"},{"issue":"1","key":"3028_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"3028_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/ckj\/sfx057","volume":"10","author":"SA Brown","year":"2017","unstructured":"Brown SA, Tyrer FC, Clarke AL, et al. Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy. Clin Kidney J. 2017;10(6):788\u201396. https:\/\/doi.org\/10.1093\/ckj\/sfx057.","journal-title":"Clin Kidney J"},{"issue":"6","key":"3028_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1590\/s1807-59322011000600012","volume":"66","author":"MC Cruz","year":"2011","unstructured":"Cruz MC, Andrade C, Urrutia M, et al. Quality of life in patients with chronic kidney disease. Clinics. 2011;66(6):991\u20135. https:\/\/doi.org\/10.1590\/s1807-59322011000600012.","journal-title":"Clinics"},{"key":"3028_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fmed.2017.00254","volume":"4","author":"E Tang","year":"2017","unstructured":"Tang E, Bansal A, Novak M, Mucsi I. Patient-reported outcomes in patients with chronic kidney disease and kidney transplant-part 1. Front Med (Lausanne). 2017;4:254. https:\/\/doi.org\/10.3389\/fmed.2017.00254.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"3028_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557\u201365. https:\/\/doi.org\/10.1200\/JCO.2015.63.0830.","journal-title":"J Clin Oncol"},{"key":"3028_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/ckj\/sfab046","volume":"14","author":"R Pecoits-Filho","year":"2021","unstructured":"Pecoits-Filho R, James G, Carrero JJ, et al. Methods and rationale of the DISCOVER CKD Global Observational Study. Clin Kidney J. 2021;14:1570\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfab046.","journal-title":"Clin Kidney J"},{"issue":"3","key":"3028_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s12325-021-02010-3","volume":"39","author":"C Pollock","year":"2022","unstructured":"Pollock C, James G, Garcia Sanchez JJ, et al. Cost of end-of-life inpatient encounters in patients with chronic kidney disease in the United States: a report from the DISCOVER CKD retrospective cohort. Adv Ther. 2022;39(3):1432\u201345. https:\/\/doi.org\/10.1007\/s12325-021-02010-3.","journal-title":"Adv Ther"},{"issue":"9","key":"3028_CR10","doi-asserted-by":"publisher","first-page":"P2059","DOI":"10.1016\/j.ekir.2022.05.033","volume":"7","author":"G James","year":"2022","unstructured":"James G, Garcia Sanchez JJ, Carrero JJ, et al. Low adherence to kidney disease: improving global outcomes 2012 CKD clinical practice guidelines despite clear evidence of utility. Kidney Int Rep. 2022;7(9):P2059\u201370. https:\/\/doi.org\/10.1016\/j.ekir.2022.05.033.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3028_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"key":"3028_CR12","unstructured":"Optum, Inc. An excerpt from the User\u2019s Manual for the SF-36v2 Health Survey, Second Edition, Chapter 3, pages 29\u201337. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/Manual%20Excerpts\/Which-Survey-To-Use.pdf. Accessed May\u00a022, 2023."},{"key":"3028_CR13","unstructured":"Optum, Inc. Optum PRO CoRE 1.5 Smart Measurement System Version 1.5. 2019."},{"issue":"4","key":"3028_CR14","first-page":"A118","volume":"3","author":"TD Topolski","year":"2006","unstructured":"Topolski TD, LoGerfo J, Patrick DL, et al. The rapid assessment of physical activity (RAPA) among older adults. Prev Chronic Dis. 2006;3(4):A118.","journal-title":"Prev Chronic Dis"},{"issue":"5","key":"3028_CR15","doi-asserted-by":"publisher","first-page":"R177","DOI":"10.1186\/ar3141","volume":"12","author":"W Zhang","year":"2010","unstructured":"Zhang W, Bansback N, Boonen A, et al. Validity of the work productivity and activity impairment questionnaire\u2013general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177. https:\/\/doi.org\/10.1186\/ar3141.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"3028_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3346\/jkms.2017.32.2.221","volume":"32","author":"E Kang","year":"2017","unstructured":"Kang E, Han M, Kim H, et al. Baseline general characteristics of the Korean chronic kidney disease: report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci. 2017;32(2):221\u201330. https:\/\/doi.org\/10.3346\/jkms.2017.32.2.221.","journal-title":"J Korean Med Sci"},{"key":"3028_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2369-12-53","volume":"12","author":"A Martinez-Castelao","year":"2011","unstructured":"Martinez-Castelao A, Gorriz JL, Portoles JM, et al. Baseline characteristics of patients with chronic kidney disease stage\u00a03 and stage\u00a04 in Spain: the MERENA observational cohort study. BMC Nephrol. 2011;12:53. https:\/\/doi.org\/10.1186\/1471-2369-12-53.","journal-title":"BMC Nephrol"},{"issue":"11","key":"3028_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2215\/CJN.04260415","volume":"10","author":"M Denker","year":"2015","unstructured":"Denker M, Boyle S, Anderson AH, et al. Chronic Renal Insufficiency Cohort Study (CRIC): overview and summary of selected findings. Clin J Am Soc Nephrol CJASN. 2015;10(11):2073\u201383. https:\/\/doi.org\/10.2215\/CJN.04260415.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"2","key":"3028_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ndt\/gfy058","volume":"34","author":"B Stengel","year":"2019","unstructured":"Stengel B, Metzger M, Combe C, et al. Risk profile, quality of life and care of patients with moderate and advanced CKD: the French CKD-REIN cohort study. Nephrol Dialy Transplant. 2019;34(2):277\u201386. https:\/\/doi.org\/10.1093\/ndt\/gfy058.","journal-title":"Nephrol Dialy Transplant"},{"issue":"5","key":"3028_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/ndt\/gfz260","volume":"35","author":"H Reichel","year":"2020","unstructured":"Reichel H, Zee J, Tu C, et al. Chronic kidney disease progression and mortality risk profiles in Germany: results from the chronic kidney disease outcomes and practice patterns study. Nephrol Dialy Transplant. 2020;35(5):803\u201310. https:\/\/doi.org\/10.1093\/ndt\/gfz260.","journal-title":"Nephrol Dialy Transplant"},{"issue":"1","key":"3028_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12882-017-0441-9","volume":"18","author":"J Yuan","year":"2017","unstructured":"Yuan J, Zou XR, Han SP, et al. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2017;18(1):23. https:\/\/doi.org\/10.1186\/s12882-017-0441-9.","journal-title":"BMC Nephrol"},{"issue":"3","key":"3028_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/sdi.12878","volume":"33","author":"B Roehm","year":"2020","unstructured":"Roehm B, Gulati G, Weiner DE. Heart failure management in dialysis patients: many treatment options with no clear evidence. Semin Dial. 2020;33(3):198\u2013208. https:\/\/doi.org\/10.1111\/sdi.12878","journal-title":"Semin Dial"},{"issue":"1","key":"3028_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bcp.13434","volume":"84","author":"A Al-Naher","year":"2018","unstructured":"Al-Naher A, Wright D, Devonald MAJ, Pirmohamed M. Renal function monitoring in heart failure \u2013 what is the optimal frequency? A narrative review. Br J Clin Pharmacol. 2018;84:5\u201317. https:\/\/doi.org\/10.1111\/bcp.13434","journal-title":"Br J Clin Pharmacol"},{"key":"3028_CR24","doi-asserted-by":"publisher","unstructured":"Kidney Disease\u00a0Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"issue":"3","key":"3028_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559\u201369. https:\/\/doi.org\/10.1016\/j.kint.2020.10.026.","journal-title":"Kidney Int"},{"key":"3028_CR26","unstructured":"National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2023. https:\/\/www.nice.org.uk\/guidance\/ng136\/chapter\/Recommendations. Accessed"},{"key":"3028_CR27","doi-asserted-by":"publisher","unstructured":"Accord Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type\u00a02 diabetes mellitus. New Engl J Med 2010;362(17):1575\u201385. https:\/\/doi.org\/10.1056\/NEJMoa1001286.","DOI":"10.1056\/NEJMoa1001286"},{"issue":"5","key":"3028_CR28","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990\u20139. https:\/\/doi.org\/10.1016\/j.kint.2022.06.013.","journal-title":"Kidney Int"},{"key":"3028_CR29","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102(5S):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"12","key":"3028_CR30","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"7","key":"3028_CR31","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bcp.14713","volume":"87","author":"S Liabeuf","year":"2021","unstructured":"Liabeuf S, Lambert O, Metzger M, et al. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: the CKD-REIN cohort study. Br J Clin Pharmacol. 2021;87(7):2967\u201376. https:\/\/doi.org\/10.1111\/bcp.14713.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3028_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003954","volume":"19","author":"BR Fletcher","year":"2022","unstructured":"Fletcher BR, Damery S, Aiyegbusi OL, et al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLoS Med. 2022;19(4): e1003954. https:\/\/doi.org\/10.1371\/journal.pmed.1003954.","journal-title":"PLoS Med"},{"issue":"6890","key":"3028_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bmj.306.6890.1437","volume":"306","author":"C Jenkinson","year":"1993","unstructured":"Jenkinson C, Coulter A, Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993;306(6890):1437\u201340. https:\/\/doi.org\/10.1136\/bmj.306.6890.1437.","journal-title":"BMJ"},{"issue":"3","key":"3028_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230512","volume":"15","author":"S Elshahat","year":"2020","unstructured":"Elshahat S, Cockwell P, Maxwell AP, et al. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLoS One. 2020;15(3): e0230512. https:\/\/doi.org\/10.1371\/journal.pone.0230512.","journal-title":"PLoS One"},{"issue":"4","key":"3028_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/pds.5398","volume":"31","author":"JM Paik","year":"2022","unstructured":"Paik JM, Patorno E, Zhuo M, et al. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data. Pharmacoepidemiol Drug Saf. 2022;31(4):467\u201375. https:\/\/doi.org\/10.1002\/pds.5398.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"3028_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.kint.2022.09.020","volume":"103","author":"JJ Carrero","year":"2023","unstructured":"Carrero JJ, Fu EL, Vestergaard SV, et al. Defining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations. Kidney Int. 2023;2023:53\u201369. https:\/\/doi.org\/10.1016\/j.kint.2022.09.020","journal-title":"Kidney Int"},{"issue":"5","key":"3028_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/fampra\/cmab070","volume":"38","author":"QS Booker","year":"2021","unstructured":"Booker QS, Austin JD, Balasubramanian BA. Survey strategies to increase participant response rates in primary care research studies. Fam Pract. 2021;38(5):699\u2013702. https:\/\/doi.org\/10.1093\/fampra\/cmab070","journal-title":"Fam Pract"}],"updated-by":[{"DOI":"10.1007\/s12325-025-03107-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03028-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03028-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03028-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:37:39Z","timestamp":1740645459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03028-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3028"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03028-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-025-03107-9","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article was revised due to retrospective open access.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-025-03107-9","URL":"https:\/\/doi.org\/10.1007\/s12325-025-03107-9","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carol Pollock reports advisory board membership for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Vifor Pharma; and speaker fees for AstraZeneca, Janssen-Cilag, Novartis, Otsuka and Vifor Pharma. Juan-Jesus Carrero reports institutional grants from Astellas, AstraZeneca and Vifor Pharma; speaker fees from AstraZeneca, Abbott and Nutricia; and consultancy for AstraZeneca and Bayer. Eiichiro Kanda is a consultant for AstraZeneca. Richard Ofori-Aseno, Hungta Chen, Juan Jose Garcia Sanchez and Surendra Pentakota are employees of and hold or may hold stock in AstraZeneca. Roberto Pecoits-Filho is an employee of Arbor Research Collaborative for Health, which receives global support for the ongoing Dialysis Outcomes and Practice Patterns Study Programs (provided without restriction on publications by a variety of funders; for details see ). Roberto Pecoits-Filho also reports: research grants from Fresenius Medical Care; nonfinancial support from Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and FibroGen; personal fees from Travere Therapeutics; and consulting fees from George Clinical outside the submitted work. Steven Fishbane reports research support and consulting fees from AstraZeneca; and research support from Akebia Inc., MegaPro Biomedical Co., Ltd., Ardelyx, Corvidia Therapeutics, Inc. and Cara Therapeutics. Carolyn S. P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from NovoNordisk and Roche Diagnostics; has served as a consultant or is on the advisory board\/steering committee\/executive committee for Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Inc., Janssen Research & Development LLC, Medscape\/WebMD Global LLC, Merck, Novartis, NovoNordisk, Prosciento Inc., Quidel Corporation, Radcliffe Group Ltd., Recardio Inc., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. Naoki Kashihara is a consultant for AstraZeneca, Boehringer Ingelheim, and Kyowa Hakko Kirin; and receives honoraria from Kyowa Hakko Kirin and Daiichi Sankyo. David C. Wheeler reports personal fees and nonfinancial support from AstraZeneca; and personal fees from Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Mundipharma, Napp, Reata Pharmaceuticals, Tricida and Vifor Fresenius.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Conference on Harmonisation, Good Clinical Practice, and the applicable legislation on noninterventional studies and observational studies. The study received central (approval numbers, Italy: 711\/19; UK, REC No. 19\/YH\/0357; Sweden, DNR 2019\u201305355; Spain 2021\/342; and USA, Pro00036594) and local (Japan) institutional review board ethics approval. The names of the central ethics committees that approved the study are Italy: Comitato Etico Indipendente Istituto Clinico Humanitas; Spain: Ethics Committee for Research with Drugs of Galicia; Sweden: Swedish Ethical Review Authority; UK: Health Research Authority; and USA: Advarra. A full list of study sites and their respective ethics committees is provided in Supplementary Table\u00a0. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}